2009 Annual Meeting
Presentations from the ASENT 11th Annual Meeting:
- Methodological Issues in Examining Cognition Across CNS Disorders
- Methodological Issues in Traumatic Brain Injury Research
- Methodological Issues and Translation Research in Traumatic Brain Injury
- Resource Allocation in Translation Neuroscience: Perspectives on Influencing the Pipeline
- Pharmacogenetics: Implications for CNS Drug Development in the 21st Century
- Pipeline Projects
- The Role of Neuroimaging in Clinical Trials and Drug Discovery
- Clinical Trials in Neurotherapeutics
To view a session, click 
to view
a PowerPoint slide presentation, 
to hear the audio,
and 
to view a video.
Thursday, March 5, 2009
Welcome
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Welcome |
Roger Porter, M.D. and Larry Alphs, Ph.D. |
6 min. 55 sec. |
|
|
|
Methodological Issues in Examining Cognition Across CNS Disorders
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Cognition as an Under-Explored Aspect of Multiple Disorders |
Richard Keefe, Ph.D., Duke University Medical Center |
4 min. 37 sec. |
|
|
|
| Cognitive Assessment in Schizophrenia Clinical Trials: MATRICS and Beyond |
Michael F. Green, Ph.D., David Geffen School of Medicine at UCLA |
24 min. 50 sec. |
|
|
|
| Psychometric Considerations and Consensus Standards for Cognitive Testing in MS |
Ralph HB Benedict, Ph.D., SUNY Buffalo |
25 min. 14 sec. |
|
|
|
| Cognitive and Behavioral Endpoints as Primary Outcome Variables in Epilepsy Clinical Trials |
David W. Loring, Ph.D., Univeristy of Florida |
24 min. 39 sec. |
|
|
|
| Application of Cognitive Assessment Methods for Bipolar Clinical Trials |
Katherine E. Burdick, Ph.D., Albert Einstein College of Medicine |
23 min. 37 sec. |
|
|
|
| Panel Discussion |
Panel |
1 hr. 31 min. 47 sec. |
|
|
|
Methodological Issues in Traumatic Brain Injury Research
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Methodological Issues in Traumatic Brain Injury |
Summary |
|
|
|
|
| Introduction to Tramatic Brain Injury |
Alan Faden, M.D., Georgetown University Medical Center |
8 min. 29 sec. |
|
|
|
| MTBI In the Civilian Population: New Frontiers in Diagnosis and Treatment |
Mark R. Lovell, Ph.D., University of Pittsburgh |
29 min. 50 sec. |
|
|
|
| Characterization and Study of Acute Military Mild Traumatic Brain Injury in the War-Zone |
Col (S) Michael M. Jaffee, M.D., Defense and Veterans Brain Injury Center |
29 min. 54 sec. |
|
|
|
| Studies of Chronic Problems after Mild TBI in Military Populations: Challenges in the Characterization of Chronic Problems and Design of Treatment Trials |
Karen A. Schwab, Ph.D., Defense and Veterans Brain Injury Center |
15 min. 21 sec. |
|
|
|
| Questions and Answers |
Panel |
15 min. 38 sec. |
|
|
|
Methodological Issues and Translation Research in Traumatic Brain Injury
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Mild TBI: Animal to Human Translation |
Douglas H. Smith, M.D., Penn Center for Brain Injury and Repair |
27 min. 42 sec. |
|
|
|
| How Do We Optimise Neurotrauma Trial Design: Where Do We Go from Here? |
Ross Bullock, M.D., Ph.D., FRCS, University of Miami Leonard M. Miller School of Medicine |
26 min. 2 sec. |
|
|
|
Dinner Symposium: Resource Allocation in Translation Neuroscience: Perspectives on Influencing the Pipeline
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Resource Allocation in Translational Neuroscience |
Tom Insel, M.D., NIMH |
15 min. 7 sec. |
|
|
|
| Financing the Neuroscience Pipeline from a VC Perspective |
Jonathan J. Fleming. Oxford Biosciences |
24 min. 15 sec. |
|
|
|
| Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009 |
Janet Vergis, A Division of Ortho-McNeil Janssen Pharmaceuticals |
16 min. 9 sec. |
|
|
|
Friday, March 6, 2009
Pharmacogentics: Implications for CNS Drug Development in the 21st Century
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Genomic /Genetic Considerations in CNS Drug Development: Current Status and Approaches "1. Basic Science Standpoint" |
Orest Hurko, M.D., Wyeth Research |
33 min. 31 sec. |
|
|
|
| Pharmacogenomics: Implications for Clinical Education |
Howard J. Federoff, M.D., Ph.D., Georgetown University |
26 min. 26 sec. |
|
|
|
Implications for Drug Development
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Pharmacogenetics of Antipsychotic Drug Response |
Anil K. Malhotra, M.D., Albert Einstein Colllege of Medicine |
28 min. 8 sec. |
|
|
|
| Shedding Light on Restless Legs Syndrome via the Human Genome: Pharmacogenomic Implications |
David B. Rye, M.D., Emory Univeristy |
29 min. 29 sec. |
|
|
|
| Pharmacogenomics: Implications for CNS Drug Development in the 21st Century |
Valerie A. Cwik, M.D., Medical Director, Muscular Dystrophy Association (MDA) |
|
|
|
|
| Phamocogenetics Biomarkers "Dividing to Conquer" |
Cristina Sampaio M.D., Ph.D., The European Medicines Agency (EMEA) |
|
|
|
|
| Panel Discussion - Part 1 |
Panel |
13 min. 36 sec. |
|
|
|
| Panel Discussion - Part 2 |
Panel |
8 min. 39 sec. |
|
|
|
Pipeline Projects - Alzheimer's Disease
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease |
J. Thomas Megerian, M.D., Ph.D., Epix Pharmaceuticals |
7 min. 25 sec. |
|
|
|
| Biomarkers for Monitoring Treatment with HDAC Inhibitors |
James Rusche, Ph.D., Repligen Corporation |
10 min. 46 sec. |
|
|
|
| ORM-12741 for Negative and Cognitive Symptoms of Schizophrenia, Depression and Alzheimer's Disease |
Juha Rouru, Ari Koivisto, Katja Kuokkanen, Jyrki Lehtimäki, Niina Jalava and Tiina Pirttilä, Orion Corporation, Orion Pharma |
6 min. 18 sec. |
|
|
|
| Phase 2 Trial of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease |
Claude Wischik, Peter Bentham (PI), Roger Staff, Alison Murray, Donald Mowat, John Storey, Damon Wischik, University of Aberdeen & TauRx Therapeutics |
10 min. 23 sec. |
|
|
|
Pipeline Projects - Neuropathic Pain & Migraine
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| YKP3089 - Novel Neurotherapeutic |
Martin Brecher, M.D., SK Life Sciences |
4 min. 23 sec. |
|
|
|
| Novel Development of IR Oxycodone HCl Tablets with Aversion® Technology |
Kenneth W Sommerville M.D., King Pharmaceuticals |
11 min. 16 sec. |
|
|
|
| MAP004 in Clinical Development: Novel and Optimized Delivery of DHE to the Lung |
Thomas Armer, M.D., MAP Pharmaceuticals |
8 min. 16 sec. |
|
|
|
| Safety and Tolerability of the MAO Inhibitor Isocarboxazid (Marplan) in the Prophylactic Treatment of Migraine |
Herbert Harris, M.D., Ph.D., Validus Pharmaceuticals |
8 min. 19 sec. |
|
|
|
Pipeline Projects - Epilepsy
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Retigabine |
Roger J. Porter, M.D., University of Pennsylvania |
6 min. 11 sec. |
|
|
|
| An Overview of the Development of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures - A Novel Experimental Sodium Channel Blocker |
Mark Versavel, M.D., Ph.D., MBA, Sepracor Inc. |
8 min. 20 sec. |
|
|
|
| 2DG - A Familiar Antiglycolytic Glucose-analog With Novel Anticonvulsant Properties |
Thomas Sutula, M.D., Ph.D., Department of Neurology, University of Wisconsin |
13 min. 59 sec. |
|
|
|
| The NeuroPace® RNS System: Clinical Development of Responsive Cortical Stimulation as a Treatment for Medically Refractory Epilepsy |
Martha J. Morrell M.D., NeuroPace, Inc. |
9 min. 56 sec. |
|
|
|
| Convection-Enhanced Delivery for the Treatment of Partial Seizures |
Michael A. Rogawski, M.D., Ph.D., University of Caifornia, Davis |
15 min. 21 sec. |
|
|
|
Pipeline Projects - Movement Disorders & Neuromuscular
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Selective Inhibitor of VMAT2 with an Attractive PK and Safety Profile for Hyperkinetic Movement Disorders |
Ajay Madan, Ph.D., Neurocrine Biosciences |
7 min. |
|
|
|
| Translational Neurobiology Application to Huntington's Diseases Therapeutics Development in Huntington's Disease: Targeting neurotrophin and Sirtuins |
Wenzhen Duan, M.D, Ph.D., Johns Hopkins University |
10 min. 16 sec. |
|
|
|
| Ataluren (PTC124TM) |
Leone Atkinson, M.D., Ph.D., PTC Therapeutics, Inc. |
16 min. 49 sec. |
|
|
|
Pipeline Projects - Spinal Cord Injury/Multiple Sclerosis
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Acorda Therapeutics: Preclinical Pipeline |
Anthony Caggiano, M.D., Ph.D., Acorda Therapeutics, Inc. |
8 min. 49 sec. |
|
|
|
Pipeline Projects - Neuro-Oncology
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| New Peptide Engineered Compounds able to Cross the Blood-Brain Barrier to Treat Brain Diseases |
Reinhard Gabathuler, Ph.D., Angiochem Inc. |
12 min. 41 sec. |
|
|
|
Pipeline Projects - Partnering with Large Pharma
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Partnering with Eli Lilly and Company |
Mary Chamberlain-Tharp, Ph.D., MBA, Eli Lilly and Company |
7 min. 49 sec. |
|
|
|
Saturday, March 7, 2009
The Role of Neuroimaging in Clinical Trials and Drug Discovery
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| The Neuroimaging Technology Revolution |
Rohit Bakshi, M.D., FAAN, Brigham & Women's Hospital, Harvard Medical School |
|
|
|
|
| Chasing Down New Treatments |
Walter Koroshetz, M.D., National Institute of Neurological Disorders and Stroke |
|
|
|
|
| Use of Magnetic Resonance Imaging In Multiple Sclerosis Trials |
Richard A. Rudick, M.D., Cleveland Clinic |
|
|
|
|
| The Role of Neuroimaging in Therapeutic Trials and Drug Discovery: Alzheimer’s Disease |
Joseph C. Masdeu, M.D., Ph.D., National Institute of Mental Health/NIH |
|
|
|
|
| The Role of Neuroimaging in Clinical Trials and Drug Discovery In Psychiatry |
Joseph C. Masdeu, M.D., Ph.D., National Institute of Mental Health/NIH |
|
|
|
|
| Panel Discussion |
Panelist |
32 min. 58sec. |
|
|
|
Clinical Trials in Neurotherapeutics
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Overview of Phase I->Phase III Fundamentals of Clinical Trials |
Roger J. Porter, M.D., University of Pennsylvania |
39 min. 39 sec. |
|
|
|
| Clinical Trial Timelines |
Cornelia Kamp, MBA., Univeristy of Rochester |
40 min. 1 sec. |
|
|
|
| Subject Recruitment & Retention |
Joyce A. Cramer, Epilepsy Therapy Project |
36 min. 52 sec. |
|
|
|
| Handling (and Preventing) Missing Data in RCTs |
Janet Wittes, Ph.D., President, Statistics Collaborative |
41 min. 27 sec. |
|
|
|
| Biomarkers and Surrogates: Underpinnings and Clinical Trial Applications |
Marc K. Walton, M.D., Ph.D., FDA |
42 min. 51 sec. |
|
|
|
| International Clinical Trials - A Regulatory Perspective |
James Ottinger, R.Ph, Vice President, Global Consulting and Compliance, Premier Research |
32 min. 19 sec. |
|
|
|
| Ethical Issues in Clinical Trials of Neurotherapeutics |
Scott Kim, M.D., Ph.D., Assistant Professor of Psychiatry, Univeristy of Michigan |
32 min. 6 sec. |
|
|
|
